1. Signaling Pathways
  2. JAK/STAT Signaling
    Stem Cell/Wnt
  3. STAT

STAT

STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The transcription factors of this family are activated by Janus kinase and dysregulation of this pathway is frequently observed in primary tumours and leads to increased angiogenesis, enhanced survival of tumours and immunosuppression. Gene knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumour surveillance. STAT proteins were originally described as latent cytoplasmic transcription factors that require phosphorylation for nuclear retention. The unphosphorylated STAT proteins shuttle between cytosol and the nucleus waiting for its activation signal. Once the activated transcription factor reaches the nucleus, it binds to consensus DNA-recognition motif called gamma-activated sites (GAS) in the promoter region of cytokine-inducible genes and activates transcription of these genes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-175013
    CDK6/9-IN-2
    Inhibitor
    CDK6/9-IN-2 is a highly active dual inhibitor of CDK6 (IC50 = 15 nM) and CDK9 (IC50 = 22 nM). CDK6/9-IN-2 is selective for CDK2, CDK8, and CDK11. CDK6/9-IN-2 inhibits the proliferation of HaCaT cells induced by IFN-γ/TNF-α and suppresses the STAT3 pathway and the expression of inflammatory factors. CDK6/9-IN-2 can alleviate psoriatic dermatitis and is useful in psoriasis research.
    CDK6/9-IN-2
  • HY-12987R
    Pimozide (Standard)
    Inhibitor
    Pimozide (Standard) is the analytical standard of Pimozide. This product is intended for research and analytical applications. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
    Pimozide (Standard)
  • HY-14592R
    Tectochrysin (Standard)
    Tectochrysin (Standard) is the analytical standard of Tectochrysin. This product is intended for research and analytical applications. Tectochrysin (Techtochrysin) is one of the major flavonoids of Alpinia oxyphylla Miquel. Tectochrysin inhibits activity of NF-κB.
    Tectochrysin (Standard)
  • HY-175201
    pro-FTY
    Inhibitor
    pro-FTY, a FTY720 (HY-12005) anticancer prodrug, is a sphingosine-1-phosphate (S1P) (HY-108496) inhibitor. pro-FTY specifically inhibits S1P signaling in cancer cells using a drug delivery system (DDS) that reacts with acrolein. pro-FTY significantly inhibits the survival of breast cancer cells, including multidrug-resistant cells and its organoids resistant to Paclitaxel (HY-B0015) or Doxorubicin (HY-15142A). pro-FTY potently suppresses tumor growth in 4T1 cells or organoids xenograft tumors mice model while avoiding lymphocytopenia.
    pro-FTY
  • HY-N0236R
    Corylin (Standard)
    Inhibitor
    Corylin (Standard) is the analytical standard of Corylin. This product is intended for research and analytical applications. Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways.
    Corylin (Standard)
  • HY-N3913
    Furowanin A
    Inhibitor
    Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells.
    Furowanin A
  • HY-W013242R
    Gondoic acid (Standard)
    Inhibitor
    Gondoic acid (Standard) is an analytical standard for Gondoic acid. This product is used for research and analytical applications. Gondoic acid (cis-11-Eicosenoic acid), a monounsaturated long-chain fatty acid, is contained in a variety of plant oils and nuts. Gondoic acid can exert anti-inflammatory activity by inhibiting the production of ROS and the PKCθ/ERK/STAT3 signaling pathway. Gondoic acid can be used as a raw material for medical supplies and a moisturizing ingredient in cosmetic creams.
    Gondoic acid (Standard)
  • HY-P10114
    STAT3-IN-24, cell-permeable
    Inhibitor
    STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3.
    STAT3-IN-24, cell-permeable
  • HY-B0667S
    Balsalazide-d3
    Balsalazide-d3 is the deuterium labeled Balsalazide (HY-B0667). Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway.
    Balsalazide-d<sub>3</sub>
  • HY-18061R
    Ochromycinone (Standard)
    Inhibitor
    Ochromycinone (Standard) ((Rac)-STA-21 (Standard)) is the analytical standard of Ochromycinone (HY-18061). This product is intended for research and analytical applications. Ochromycinone is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.
    Ochromycinone (Standard)
  • HY-B1436S1
    Nifuroxazide-13C6
    Inhibitor
    Nifuroxazide-13C6 is the 13C6 labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
    Nifuroxazide-<sup>13</sup>C<sub>6</sub>
  • HY-RS13896
    STAT6 Human Pre-designed siRNA Set A
    Inhibitor

    STAT6 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STAT6 Human Pre-designed siRNA Set A
  • HY-N8107
    Matairesinol monoglucoside
    Inhibitor
    Matairesinol monoglucoside, a lignan compound, exhibits low activity on IFN-γ/STAT1 and IL-6/STAT3 signaling pathways with inhibition ratio of 5.8% and 7.0%, respectively.
    Matairesinol monoglucoside
  • HY-111077
    INCB16562
    Inhibitor
    INCB16562 is an orally active and selective inhibitor against JAK1/2 markedly selective over JAK3. INCB16562 potently inhibits interleukin-6 (IL-6)-induced phosphorylation of STAT3. Additionally, INCB16562 inhibits the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6–induced growth of primary bone marrow-derived plasma cells. INCB16562 antagonizes the growth of myeloma xenografts in mice with antitumor activity. INCB16562 is promising for research of multiple myeloma.
    INCB16562
  • HY-W414644
    Fluacrypyrim
    Inhibitor
    Fluacrypyrim, a Miticide, is a STAT3 inhibitor. Fluacrypyrim significantly increases the protein tyrosine phosphatases(PTPs) activity. Fluacrypyrim inhibits the growth of leukemia cells by a predominant G1 arrest with significant decrease of the protein and mRNA levels of cyclin D1. Fluacrypyrim selectively inhibits STAT3 signaling, inducing growth arrest and apoptosis in STAT3-dependent cancer cells. Fluacrypyrim mitigates IR-induced hematopoietic system injury mainly by preventing apoptosis in the HSCs. Fluacrypyrim demonstrates significant analgesic and anti-inflammatory effects by inhibiting uterine smooth muscle contraction and inflammatory responses.
    Fluacrypyrim
  • HY-170947
    Antitumor agent-195
    Inhibitor
    Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model.
    Antitumor agent-195
  • HY-147048
    STAT3 degrader-1
    STAT3 degrader-1 (compound 295) is a potent STAT3 degrader. STAT3 degrader-1 can be used for researching anticancer. STAT3 degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    STAT3 degrader-1
  • HY-175298
    STAT-3/c-Src-IN-1
    Inhibitor
    STAT-3/c-Src-IN-1 (Compound 12d) is a dual STAT-3 (IC50=0.844 μM) and c-Src (IC50=0.268 μM) inhibitor. STAT-3/c-Src-IN-1 blocks tumor cell proliferation, migration, and angiogenesis signaling pathways. STAT-3/c-Src-IN-1 exhibits potent anti-proliferative activity against melanoma (SK-MEL-2) and CNS cancer (SNB-75) cell lines (GI50=-5.75 μM and -5.63 μM), inducing tumor cell apoptosis via G0/G1 and G2/M phase cell cycle arrest. STAT-3/c-Src-IN-1 is promising for research of melanoma and glioblastoma.
    STAT-3/c-Src-IN-1
  • HY-146728
    STAT3-IN-10
    Inhibitor
    STAT3-IN-10 is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, induces cancer cells apoptosis.
    STAT3-IN-10
  • HY-158439
    anti-TNBC agent-7
    Modulator
    anti-TNBC agent-7 (Compound 13c) possesses anticancer activity, serving as a molecular probe to recognize and regulate the signal transduction of the USP21/JAK2/STAT3 axis, exhibiting nanomolar-level cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC).
    anti-TNBC agent-7
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.